New findings in preventing recurrence and improving renal function in AHUS patients after renal transplantation treated with eculizumab: a systemic review and meta-analyses
Background The long-term mortality of kidney transplantation patients with atypical hemolytic uremic syndrome remains high, and the efficacy of the main treatment eculizumab is still controversial.Objective A comprehensive systematic review and meta-analysis of clinical trials using eculizumab in re...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | Renal Failure |
| Online Access: | https://www.tandfonline.com/doi/10.1080/0886022X.2023.2231264 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850187202349236224 |
|---|---|
| author | Zheng Chun Tang Huang Hui Chunru Shi Xiangmei Chen |
| author_facet | Zheng Chun Tang Huang Hui Chunru Shi Xiangmei Chen |
| author_sort | Zheng Chun Tang |
| collection | DOAJ |
| description | Background The long-term mortality of kidney transplantation patients with atypical hemolytic uremic syndrome remains high, and the efficacy of the main treatment eculizumab is still controversial.Objective A comprehensive systematic review and meta-analysis of clinical trials using eculizumab in renal transplant patients with atypical hemolytic uremic syndrome was conducted to evaluate the efficacy of this therapy and its impact on renal function.Methods A comprehensive systematic search was conducted across multiple reputable databases, including Ovid (MEDLINE, EMBASE), PubMed, and the Cochrane Library (since database inception), to identify relevant studies exploring the use of eculizumab in patients with atypical hemolytic uremic kidney transplantation. Various renal function parameters, such as dialysis, rejection, glomerular filtration rate, serum creatinine, lactate dehydrogenase, and platelet count, along with patient relapse rates, were extracted and summarized using a combination of robust statistical methods, including fixed effects, random effects, and general inverse variance methods.Result Eighteen trials with 618 subjects were analyzed. Our analysis suggests that the use of eculizumab is associated with a reduced likelihood of AHUS recurrence (odds ratio (OR) = 0.05, 95% CI: 0.00–0.13), as well as a significant reduction in the need for dialysis (odds ratio (OR) = 0.13, 95% CI: 0.01–0.32). Additionally, eculizumab treatment led to lower serum creatinine levels (mean differences (MD) = 126.931μmoI/L, 95% CI: 115.572μmoI/L–138.290μmoI/L) and an improved glomerular filtration rate (mean differences (MD) = 59.571 ml/min, 95% CI: 57.876 ml/min–61.266 mL/min). Our results also indicate that the use of eculizumab reduces the likelihood of rejection (odds ratio (OR) = 0.09, 95% CI: 0.01–0.22). Furthermore, the drug was effective in improving platelet counts (×10∧9/L) (mean differences (MD) = 163.421, 95% CI: 46.998–279.844) and lactate dehydrogenase levels (mean differences (MD) = 336.608 U/L, 95% CI: 164.816 U/L–508.399 U/L).Conclusions Based on the meta-analysis, treatment with eculizumab can reduce dialysis rates and improve patients’ quality of life by enhancing renal function. |
| format | Article |
| id | doaj-art-68680507f47a4f87a10bbbb463b9975b |
| institution | OA Journals |
| issn | 0886-022X 1525-6049 |
| language | English |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Renal Failure |
| spelling | doaj-art-68680507f47a4f87a10bbbb463b9975b2025-08-20T02:16:10ZengTaylor & Francis GroupRenal Failure0886-022X1525-60492023-12-0145110.1080/0886022X.2023.2231264New findings in preventing recurrence and improving renal function in AHUS patients after renal transplantation treated with eculizumab: a systemic review and meta-analysesZheng Chun Tang0Huang Hui1Chunru Shi2Xiangmei Chen3Guangdong Pharmaceutical University, Guangzhou, ChinaGuangdong Pharmaceutical University, Guangzhou, ChinaGuangdong Pharmaceutical University, Guangzhou, ChinaRenal Medicine Department, Chinese PLA General Hospital, Beijing, ChinaBackground The long-term mortality of kidney transplantation patients with atypical hemolytic uremic syndrome remains high, and the efficacy of the main treatment eculizumab is still controversial.Objective A comprehensive systematic review and meta-analysis of clinical trials using eculizumab in renal transplant patients with atypical hemolytic uremic syndrome was conducted to evaluate the efficacy of this therapy and its impact on renal function.Methods A comprehensive systematic search was conducted across multiple reputable databases, including Ovid (MEDLINE, EMBASE), PubMed, and the Cochrane Library (since database inception), to identify relevant studies exploring the use of eculizumab in patients with atypical hemolytic uremic kidney transplantation. Various renal function parameters, such as dialysis, rejection, glomerular filtration rate, serum creatinine, lactate dehydrogenase, and platelet count, along with patient relapse rates, were extracted and summarized using a combination of robust statistical methods, including fixed effects, random effects, and general inverse variance methods.Result Eighteen trials with 618 subjects were analyzed. Our analysis suggests that the use of eculizumab is associated with a reduced likelihood of AHUS recurrence (odds ratio (OR) = 0.05, 95% CI: 0.00–0.13), as well as a significant reduction in the need for dialysis (odds ratio (OR) = 0.13, 95% CI: 0.01–0.32). Additionally, eculizumab treatment led to lower serum creatinine levels (mean differences (MD) = 126.931μmoI/L, 95% CI: 115.572μmoI/L–138.290μmoI/L) and an improved glomerular filtration rate (mean differences (MD) = 59.571 ml/min, 95% CI: 57.876 ml/min–61.266 mL/min). Our results also indicate that the use of eculizumab reduces the likelihood of rejection (odds ratio (OR) = 0.09, 95% CI: 0.01–0.22). Furthermore, the drug was effective in improving platelet counts (×10∧9/L) (mean differences (MD) = 163.421, 95% CI: 46.998–279.844) and lactate dehydrogenase levels (mean differences (MD) = 336.608 U/L, 95% CI: 164.816 U/L–508.399 U/L).Conclusions Based on the meta-analysis, treatment with eculizumab can reduce dialysis rates and improve patients’ quality of life by enhancing renal function.https://www.tandfonline.com/doi/10.1080/0886022X.2023.2231264 |
| spellingShingle | Zheng Chun Tang Huang Hui Chunru Shi Xiangmei Chen New findings in preventing recurrence and improving renal function in AHUS patients after renal transplantation treated with eculizumab: a systemic review and meta-analyses Renal Failure |
| title | New findings in preventing recurrence and improving renal function in AHUS patients after renal transplantation treated with eculizumab: a systemic review and meta-analyses |
| title_full | New findings in preventing recurrence and improving renal function in AHUS patients after renal transplantation treated with eculizumab: a systemic review and meta-analyses |
| title_fullStr | New findings in preventing recurrence and improving renal function in AHUS patients after renal transplantation treated with eculizumab: a systemic review and meta-analyses |
| title_full_unstemmed | New findings in preventing recurrence and improving renal function in AHUS patients after renal transplantation treated with eculizumab: a systemic review and meta-analyses |
| title_short | New findings in preventing recurrence and improving renal function in AHUS patients after renal transplantation treated with eculizumab: a systemic review and meta-analyses |
| title_sort | new findings in preventing recurrence and improving renal function in ahus patients after renal transplantation treated with eculizumab a systemic review and meta analyses |
| url | https://www.tandfonline.com/doi/10.1080/0886022X.2023.2231264 |
| work_keys_str_mv | AT zhengchuntang newfindingsinpreventingrecurrenceandimprovingrenalfunctioninahuspatientsafterrenaltransplantationtreatedwitheculizumabasystemicreviewandmetaanalyses AT huanghui newfindingsinpreventingrecurrenceandimprovingrenalfunctioninahuspatientsafterrenaltransplantationtreatedwitheculizumabasystemicreviewandmetaanalyses AT chunrushi newfindingsinpreventingrecurrenceandimprovingrenalfunctioninahuspatientsafterrenaltransplantationtreatedwitheculizumabasystemicreviewandmetaanalyses AT xiangmeichen newfindingsinpreventingrecurrenceandimprovingrenalfunctioninahuspatientsafterrenaltransplantationtreatedwitheculizumabasystemicreviewandmetaanalyses |